GreenLight Biosciences Holdings
GRNANASDAQHealthcare
$0.30
$-0.00(-0.03%)
Market Cap$45428456
P/E Ratio—
52W High$5.9
52W Low$0.177
GreenLight Biosciences Holdings (GRNA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GRNA · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2023Report Date: May 11, 2023EPS Actual
-$0.19
Est. -$0.15 · -26.7%
Revenue
$0.00B
Est. $0.00B · +282.0%
Fiscal Period
Q2 FY2023
FY ends December
Report Date
May 11, 2023
After Market Close
▼ Miss EPS▲ Beat Revenue
GRNA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2024 | May 9, 2024 | — | — | — | — | — | — |
| ◌ Q1 FY2024 | Mar 26, 2024 | — | — | — | — | — | — |
| ◌ Q4 FY2023 | Nov 7, 2023 | — | — | — | — | — | — |
| ◌ Q3 FY2023 | Aug 14, 2023 | — | — | — | — | $0.00B | — |
| ▼ Q2 FY2023 | May 11, 2023 | -$0.15 | -$0.19 | -26.7% | $0.00B | $0.00B | +282.0% |
| ▼ Q1 FY2023 | Mar 28, 2023 | $0.25 | -$0.26 | -204.0% | $0.00B | $0.00B | +194.7% |
| ▲ Q4 FY2022 | Nov 9, 2022 | -$0.28 | -$0.27 | +3.6% | $0.00B | $0.00B | -2.5% |
| — Q3 FY2022 | Sep 26, 2022 | — | -$0.42 | — | $0.00B | — | — |
Q2 FY2024
May 9, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 26, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 7, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 14, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2023
May 11, 2023Miss
EPS Actual
-$0.19
EPS Est.
-$0.15
EPS Surpr.
-26.7%
Revenue
$0.00B
Q1 FY2023
Mar 28, 2023Miss
EPS Actual
-$0.26
EPS Est.
$0.25
EPS Surpr.
-204.0%
Revenue
$0.00B
Q4 FY2022
Nov 9, 2022Beat
EPS Actual
-$0.27
EPS Est.
-$0.28
EPS Surpr.
+3.6%
Revenue
$0.00B
Q3 FY2022
Sep 26, 2022
EPS Actual
-$0.42
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
No analyst estimates available for GRNA.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2023 | May 11, 2023 | -26.7% | $0.24 | $0.20 | -16.35% |
| ▼ Q1 FY2023 | Mar 28, 2023 | -204.0% | $0.44 | $0.45 | +2.47% |
| ▲ Q4 FY2022 | Nov 9, 2022 | +3.6% | $2.00 | $2.00 | +0.00% |
| — Q3 FY2022 | Sep 26, 2022 | — | $1.92 | $2.27 | +18.23% |
| — Q1 FY2022 | Mar 31, 2022 | — | $9.82 | $9.63 | -1.93% |
| — Q4 FY2021 | Dec 31, 2021 | — | $9.92 | $9.92 | +0.00% |
| — Q3 FY2021 | Sep 30, 2021 | — | $9.90 | $9.89 | -0.10% |
| — Q2 FY2021 | Jun 30, 2021 | — | $9.79 | $9.81 | +0.20% |
Q2 FY2023-16.35%
Report Date
May 11, 2023
EPS Beat/Miss
-26.7%
Price Before
$0.24
Price After
$0.20
Q1 FY2023+2.47%
Report Date
Mar 28, 2023
EPS Beat/Miss
-204.0%
Price Before
$0.44
Price After
$0.45
Q4 FY2022+0.00%
Report Date
Nov 9, 2022
EPS Beat/Miss
+3.6%
Price Before
$2.00
Price After
$2.00
Q3 FY2022+18.23%
Report Date
Sep 26, 2022
EPS Beat/Miss
—
Price Before
$1.92
Price After
$2.27
Q1 FY2022-1.93%
Report Date
Mar 31, 2022
EPS Beat/Miss
—
Price Before
$9.82
Price After
$9.63
Q4 FY2021+0.00%
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
$9.92
Price After
$9.92
Q3 FY2021-0.10%
Report Date
Sep 30, 2021
EPS Beat/Miss
—
Price Before
$9.90
Price After
$9.89
Q2 FY2021+0.20%
Report Date
Jun 30, 2021
EPS Beat/Miss
—
Price Before
$9.79
Price After
$9.81
Avg Beat Reaction+0.00%
Avg Miss Reaction-6.94%
Beat Rate1 / 8 quarters
Largest Move+18.23% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GRNA ends December
GreenLight Biosciences Holdings (GRNA) most recently reported earnings on May 11, 2023 for Q2 FY2023, posting EPS of $-0.19 — missing the analyst consensus of $-0.15 by -26.7%. The next GRNA earnings date is expected around September 1, 2026.
Each quarter, investors track GRNA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GRNA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GRNA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GRNA earnings · 5 questionsGreenLight Biosciences Holdings's next earnings report is expected around September 1, 2026. GRNA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GRNA historically reports after market close (AMC).
GRNA earnings datewhen is GRNA earningsGRNA next earnings datewhen does GRNA report earningsGRNA earnings calendar
▸ Source: FMP · GreenLight Biosciences Holdings SEC filings · US GAAP · GreenLight Biosciences Holdings SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026